Literature DB >> 20645951

Optimal timing for the administration of intranasal dexmedetomidine for premedication in children.

V M Yuen1, Theresa W Hui, M G Irwin, T-J Yao, G L Wong, M K Yuen.   

Abstract

Previous studies have shown that 1 μg.kg(-1) intranasal dexmedetomidine produces significant sedation in children aged between 2 and 12 years. This investigation was designed to evaluate the onset time. One hundred children aged 1-12 years of ASA physical status 1-2 undergoing elective surgery were randomly allocated to five groups. Patients in groups A to D received intranasal dexmedetomidine 1 μg.kg(-1) . Patients in Group E received intranasal placebo (0.9% saline). Children from groups A, B, C, D and E had intravenous cannulation attempted at 30, 45, 60, 75 and 45 min respectively after intranasal drug or placebo administration. Vital signs, behaviour and sedation status of the children were assessed regularly until induction of anaesthesia. More children from groups A to D achieved satisfactory sedation at the time of cannulation when compared to group E (p < 0.001). The proportion of children who achieved satisfactory sedation was not significantly different among groups A to D. Overall 62% of the children who received intranasal dexmedetomidine had satisfactory sedation at the time of cannulation. The median (95% CI) time for onset of sedation was 25 (25-30) min. The median (95% CI) duration of sedation was 85 (55-100) min.
© 2010 The Authors. Journal compilation © 2010 The Association of Anaesthetists of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20645951     DOI: 10.1111/j.1365-2044.2010.06453.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  34 in total

1.  A Comparison of Intranasal Dexmedetomidine and Dexmedetomidine Plus Buccal Midazolam for Non-painful Procedural Sedation in Children with Autism.

Authors:  Bi Lian Li; Vivian Man-Ying Yuen; Na Zhang; Huan Huan Zhang; Jun Xiang Huang; Si Yuan Yang; Jeffery W Miller; Xing Rong Song
Journal:  J Autism Dev Disord       Date:  2019-09

2.  Comparison between intranasal dexmedetomidine and intranasal ketamine as premedication for procedural sedation in children undergoing MRI: a double-blind, randomized, placebo-controlled trial.

Authors:  Prakhar Gyanesh; Rudrashish Haldar; Divya Srivastava; Prashant Mohan Agrawal; Akhilesh Kumar Tiwari; P K Singh
Journal:  J Anesth       Date:  2013-06-26       Impact factor: 2.078

3.  Intranasal Dexmedetomidine as a Sedative for Pediatric Procedural Sedation.

Authors:  Natalie Behrle; Esma Birisci; Jordan Anderson; Sara Schroeder; Abdallah Dalabih
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jan-Feb

4.  Bioavailability of dexmedetomidine after intranasal administration.

Authors:  Timo Iirola; Sanna Vilo; Tuula Manner; Riku Aantaa; Maria Lahtinen; Mika Scheinin; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2011-02-12       Impact factor: 2.953

5.  Pain management following myringotomy and tube placement: intranasal dexmedetomidine versus intranasal fentanyl.

Authors:  Elisabeth Dewhirst; Gina Fedel; Vidya Raman; Julie Rice; N'Diris Barry; Kris R Jatana; Charles Elmaraghy; Meredith Merz; Joseph D Tobias
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2014-04-16       Impact factor: 1.675

6.  Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects.

Authors:  Heedoo Yoo; Timo Iirola; Sanna Vilo; Tuula Manner; Riku Aantaa; Maria Lahtinen; Mika Scheinin; Klaus T Olkkola; William J Jusko
Journal:  Eur J Clin Pharmacol       Date:  2015-08-02       Impact factor: 2.953

7.  Dexmedetomidine: New avenues.

Authors:  Anju Grewal
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2011-07

8.  Premedication: Is clonidine the answer?

Authors:  Senthil Gopalakrishnan; Joseph D Tobias
Journal:  Saudi J Anaesth       Date:  2012-01

9.  Circulating microRNA-30a-5p, microRNA-101-3p, microRNA-140-3p and microRNA-141-3p as potential biomarkers for dexmedetomidine response in pediatric patients.

Authors:  Xinmei Cai; Bilian Li; Wei Wei; Yanping Guan; Xue Bai; Min Huang; Yaying Huang; Lili Rong; Xingrong Song; Guoping Zhong
Journal:  Eur J Clin Pharmacol       Date:  2021-07-03       Impact factor: 2.953

10.  Intranasal dexmedetomidine for paediatric sedation for diagnostic magnetic resonance imaging studies.

Authors:  Uday S Ambi; Chhaya Joshi; Anilkumar Ganeshnavar; Es Adarsh
Journal:  Indian J Anaesth       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.